Q-omics provides the consensus-scored IGLV3-26 profile across patient tissues and cancer cell-line models. IGLV3-26 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IGLV3-26 is differentially expressed in 2, with the highest sampling consensus in LUAD. Additionally, IGLV3-26 RNA expression shows 6,016 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, LUAD, and STAD as cancer lineages where IGLV3-26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGLV3-26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGLV3-26 survival associations across molecular data types. IGLV3-26 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGLV3-26 RNA expression–survival associations across cancer types. High IGLV3-26 expression shows unfavorable associations in STAD, KIRP and GBM, but favorable associations in HNSC, SKCM and OV. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for IGLV3-26 RNA expression.
This table summarizes IGLV3-26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for IGLV3-26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGLV3-26 shows lower tumor expression in LUSC and higher tumor expression in LUAD. The LUAD box plot shows higher IGLV3-26 RNA expression in tumor versus normal tissue (log2 FC = +0.066, t-test p = .005).
This table shows molecular features associated with IGLV3-26 in patient tissues and cancer cell lines. In patient samples, IGLV3-26 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
